Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
根据最新的财务报表(Form-10K),Bright Minds Biosciences Inc. 的总资产为 $84,净损失为 $-12
DRUG 的关键财务比率是什么?
Bright Minds Biosciences Inc. 的流动比率是 42,净利 margin 为 0,每股销售为 $0。
Bright Minds Biosciences Inc. 的收入按细分市场或地理位置如何划分?
Bright Minds Biosciences Inc. 最大收入来源是 Capital Equipment,在最近的收益报告中收入为 315,547,000。就地区而言, United States 是 Bright Minds Biosciences Inc. 的主要市场,收入为 244,774,000。
Bright Minds Biosciences Inc. 是否盈利?
不,根据最新的财务报表,Bright Minds Biosciences Inc. 的净损失为 $-12